Literature DB >> 26963594

Fine-Needle Aspiration Followed by Core-Needle Biopsy in the Same Setting: Modifying Our Approach.

Amani A Joudeh1, Sameera Q Shareef, Mousa A Al-Abbadi.   

Abstract

Fine-needle aspiration biopsy (FNAB) is a well-established initial diagnostic tool. However, in some instances limitations and shortcomings arise, making it insufficient for determining a specific diagnosis. Consequently, patients have to undergo another diagnostic procedure. The second procedure is either repeat FNAB, core-needle or open biopsy, and can be inconvenient and costly. In some centers, the FNAB is immediately followed by core-needle biopsy (CNB) in the same setting after assuring adequacy on the initial FNAB utilizing rapid on-site specimen evaluation (ROSE). It is argued that implementing such an approach will eventually have additional critical advantages that include the following: (a) it is more convenient to patients to have both procedures in one visit, (b) the tissue procured by both procedures will be more adequate, enabling cytopathologists to reach an accurate diagnosis, and (c) it is ultimately a cost-effective approach if we take into consideration the avoidance of a potential second more invasive diagnostic procedure. Since we are living in an era of patient-centered medicine coupled with cost-cutting strategies, we present here a brief review of the topic with analysis of this alternative approach, review of the pertinent literature and shed light on a few scenarios that justify this approach.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 26963594     DOI: 10.1159/000444386

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  8 in total

1.  Endoscopic ultrasound-guided tissue acquisition for splenic lesions: A systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Xiao Pan; Shu Huang; Peiling Gan; Lei Shi; Huifang Xia; Xinyi Zeng; Han Zhang; Muhan Lü; Xian Zhou; Xiaowei Tang
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

2.  Risk of Malignancy in Breast FNAB Categories, Classified According to the Newly Proposed International Academy of Cytology (IAC) Yokohama System.

Authors:  Mahwish Niaz; Azmat Ali Khan; Safina Ahmed; Rabia Rafi; Hassan Salim; Kashaf Khalid; Faiza Kazi; Awais Anjum; Yasir Waheed
Journal:  Cancer Manag Res       Date:  2022-05-07       Impact factor: 3.602

Review 3.  Minimally invasive biopsy in retroperitoneal tumors.

Authors:  Radu Dragos Marcu; Camelia Cristina Diaconu; Traian Constantin; Bogdan Socea; Florentina Ionita-Radu; Dan Liviu Dorel Mischianu; Ovidiu Gabriel Bratu
Journal:  Exp Ther Med       Date:  2019-09-18       Impact factor: 2.447

4.  Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing.

Authors:  Luis E De Las Casas; David G Hicks
Journal:  Am J Clin Pathol       Date:  2021-05-18       Impact factor: 2.493

5.  Comparison of fine-needle cytologic diagnosis between the left and right liver lobes of dogs and cats with diffuse liver disease.

Authors:  Nardtiwa Chaivoravitsakul; Katriya Chankow; Kongthit Horoongruang; Luksamee Limpongsai; Artima Tantarawanich; Latticha Pluemhathaikij; Kasem Rattanapinyopituk; Kris Angkanaporn
Journal:  Vet World       Date:  2021-10-21

6.  Biopsy Ratio of Suspected to Confirmed Sarcoma Diagnosis.

Authors:  Nasian Mosku; Philip Heesen; Gabriela Studer; Beata Bode; Vito Spataro; Natalie D Klass; Lars Kern; Mario F Scaglioni; Bruno Fuchs
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

7.  Conformity of Fine Needle Aspiration Biopsy (FNAB) and Core Needle Biopsy (CNB) in peripheral lung tumor patients: A cross-sectional study.

Authors:  Isnin Anang Marhana; Kadek Widianiti; Etty Hary Kusumastuti
Journal:  Ann Med Surg (Lond)       Date:  2022-03-05

Review 8.  Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Authors:  John E Mullinax; Michael E Egger; Martin McCarter; Bradley J Monk; Eric M Toloza; Susan Brousseau; Madan Jagasia; Amod Sarnaik
Journal:  Cancer J       Date:  2022 Jul-Aug 01       Impact factor: 2.074

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.